- Home
- GNLX vs ZURA Comparison
GNLX vs ZURA Comparison
Compare GNLX & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- ZURA
- Stock Information
- Founded
- GNLX 2001
- ZURA 2022
- Country
- GNLX United States
- ZURA United States
- Employees
- GNLX N/A
- ZURA N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNLX Health Care
- ZURA Health Care
- Exchange
- GNLX Nasdaq
- ZURA Nasdaq
- Market Cap
- GNLX 128.0M
- ZURA 137.2M
- IPO Year
- GNLX 2023
- ZURA N/A
- Fundamental
- Price
- GNLX $5.90
- ZURA $4.61
- Analyst Decision
- GNLX Strong Buy
- ZURA Buy
- Analyst Count
- GNLX 4
- ZURA 8
- Target Price
- GNLX $19.75
- ZURA $10.43
- AVG Volume (30 Days)
- GNLX 350.8K
- ZURA 584.8K
- Earning Date
- GNLX 11-05-2025
- ZURA 11-07-2025
- Dividend Yield
- GNLX N/A
- ZURA N/A
- EPS Growth
- GNLX N/A
- ZURA N/A
- EPS
- GNLX N/A
- ZURA N/A
- Revenue
- GNLX N/A
- ZURA N/A
- Revenue This Year
- GNLX N/A
- ZURA N/A
- Revenue Next Year
- GNLX N/A
- ZURA N/A
- P/E Ratio
- GNLX N/A
- ZURA N/A
- Revenue Growth
- GNLX N/A
- ZURA N/A
- 52 Week Low
- GNLX $1.99
- ZURA $0.97
- 52 Week High
- GNLX $8.54
- ZURA $4.85
- Technical
- Relative Strength Index (RSI)
- GNLX 45.83
- ZURA 70.10
- Support Level
- GNLX $4.34
- ZURA $3.34
- Resistance Level
- GNLX $6.12
- ZURA $3.73
- Average True Range (ATR)
- GNLX 0.85
- ZURA 0.30
- MACD
- GNLX -0.32
- ZURA 0.04
- Stochastic Oscillator
- GNLX 36.41
- ZURA 100.00
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.